Beijing Senoki Pharmaceuticals Co., Inc. variety SNG1153 approved for clinical trials in the U.S.

Recently, Beijing ShengnokiPharmaceutical(Technology LimitedCompany(receiving notice from the U.SFoodMedicines(
FDA
()), the company's variety SNG1153 is allowed to conduct clinicaltrialin the United StatesSNG1153, as an anti-tumordrug(developed for patients with advanced cancer, is the company's second fully independent intellectual property rights after the company with fully independent intellectual property rights of anti-tumornew drug(material) about SNG1153
SNG1153 is a chemical synthetic (derivative, directly killing tumors), in vitro experiments observed SNG1153 can inhibit liver cancer, lung cancer, melanoma, multiple myeloma and other tumors The proliferation of cell line, in animal experiments, it was observed that SNG1153 can inhibit tumor growth in human-derived hepatocellular carcinoma HepG2 naked rat liver in situ transplant tumor model and human-derived non-small cell lung cancer Spc-A-1 naked mouse subtherial transplant tumor model sNG1153 has an important immune regulation effect, can inhibit tumor growth of rat-derived melanoma B16/F10 homologous mouse subtheritous tumor model, and reduce the expression of PD-L1 and other molecules, providing more choices for tumor immunotherapy As a global independent intellectual property rights of Shengnoki varieties, SNG1153 was approved by the former State Administration of Food and Drug Administration (CFDA) clinical approval in May 2018, this time approved for clinical trials in the United States, marking the senocoki anti-tumor drug research into the fast track of internationalization will soon launch clinical trials at the Research and Development Center in Boston, USA, in the hope of further internationalizing the small molecule immunoinnovation drug SNG1153 and making new discoveries in future immuno-combination therapy